Form 4 for PLX Protalix BioTherapeutics, Inc.
Accepted 2022-02-28 00:00:00 ET · period of report 2022-02-25 · accession 0001104659-22-028157 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2022-02-28 | 2022-02-25 | PLX | Bashan Dror | Pres, CEO, Dir | A - Grant | — | +637.5K | 1.09M | +142% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-02-25 | A | A | 637,531 | — | 1,085,458 | I By Trust | — | — | (F1) Represents restricted shares of common stock of Protalix BioTherapeutics, Inc., awarded to the employee under its Amended and Restated 2006 Stock Incentive Plan, as amended June 7, 2020. (F2) To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee. |